Scientists edited the promoter of the rice gene OsGTL1 to lower stomatal density, raising instantaneous water use efficiency ...
CRISPR Therapeutics appointed Andrew J. Silver as Chief Financial Officer and principal financial officer on October 19, 2026 ...
CRISPR Therapeutics and Vertex Pharmaceuticals have noted that the medicine currently has an addressable market of roughly 60 ...
Isaacson argues that who patents, regulates, and profits from gene editing now matters as much as the science, because rewriting human heredity is no longer theoretical.
Zacks Investment Research on MSN
Investors heavily search CRISPR Therapeutics AG (CRSP): Here is what you need to know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...
Spread the loveImagine looking in the mirror and seeing a younger version of yourself, not just cosmetically, but at a ...
Spread the loveImagine turning back the clock, not on your watch, but on your very own cells. It sounds like something ...
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.39, marking a -1.2% move from the previous day.
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.89, moving 1.21% from the previous trading session.
ERS Genomics Limited ('ERS Genomics'), the CRISPR licensing company, today announced that it has signed a non-exclusive ...
Called Cas12a2, the CRISPR system had some distinctive properties. Rather than editing cells’ DNA when prompted by a guide RNA, as CRISPR-Cas9 does, Cas12a2 indiscriminately shreds it, ultimately ...
H.C. Wainwright reiterated a USD 80.00 target for CRISPR Therapeutics on October 9, 2026. The USD 80.00 target stood 60.39 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results